icon
icon
icon
icon
Upgrade
icon

Merck & Co., Inc. (MRK.US) terminated a phase III study evaluating the combination of PD-1+TIGIT for the first-line treatment of advanced small cell lung cancer.

AInvestFriday, Aug 9, 2024 9:30 am ET
1min read

August 8, 2023, Merck & Co., Inc. (MRK.US) announced that it will discontinue the Phase III KeyVibe-008 study based on the recommendation of the Independent Data Monitoring Committee (IDMC). The study was designed to evaluate the efficacy and safety of the PD-1+TIGIT combination (vibostolimab+K drug) versus atezolizumab+K drug in the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).

The primary endpoint of the study was overall survival (OS), and key secondary endpoints included progression-free survival (PFS), objective response rate (ORR), and duration of response (DOR). The prespecified analysis showed that the study did not meet the primary endpoint of OS. In addition, the vibostolimab group had a higher rate of adverse events compared to the control group.

The data showed that vibostolimab is a TIGIT-targeting monoclonal antibody developed by Merck & Co., Inc. that blocks the binding of TIGIT receptor to its ligand (CD112 and CD155) to restore antitumor activity and activate T lymphocytes that help destroy tumor cells.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.